Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress

Kidney International

Volumn 63, Issue 2, 2003, Pages 617-623

  Frank, Helga ^a,b   Schobel, Hans Paul ^a   Vitkowsky, Jan ^a   Schmieder, Roland E ^a   Heusser, Karsten ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

AT1 antagonism; Blood pressure; Cardiopulmonary stress; Hypertension; Neurohumoral system; Renal hemodynamics; Water homeostasis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; EPROSARTAN; NEUROHORMONE; PLACEBO;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; MALE; PRESSORECEPTOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; STANDING; STRESS; TIME;

EID: 0037249426     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00760.x     Document Type: Article

References (38)

1. FERGUSON DW, THAMES MD, MARK AL: Effects of propranolol on reflex vascular responses to orthostatic stress in humans. Role of ventricular baroreceptors. Circulation 67:802-807, 1983
2. OREN RM, SCHOBEL HP, WEISS RM, et al: Importance of left atrial baroreceptors in the cardiopulmonary baroreflex of normal humans. J Appl Physiol 74:2672-2680, 1993
3. MILLER JA, FLORAS JS, SKORECKI KL, et al: Renal and humoral responses to sustained cardiopulmonary baroreceptor deactivation in humans. Am J Physiol 260:R642-R648, 1991
4. SCHMIEDER RE, SCHOBEL HP, MESSERLI FH: Central blood volume: A determinant of early cardiac adaptation in arterial hypertension? J Am Coll Cardiol 26:1692-1698, 1995
5. WEBER MA: Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens 15:31-36, 1997
6. LOUTZENHISER R, EPSTEIN M, HAYASHI K, et al: Characterization of the renal microvascular effects of angiotensin II antagonist DuP 753: Studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 4:309-314, 1991
7. FONTOURA BM, NUSSENZVEIG DR, TIMMERMANS PB, et al: Dup 753 is a potent nonpeptide antagonist of angiotensin II receptors in isolated perfused rat kidney and cultured renal cells. Am J Hypertens 4:303-308, 1991
8. FENOY FJ, MILICIC I, SMITH RD, et al: Effects of Dup 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens 4(4 Pt. 2):321S-326S, 1991
9. ZHUO J, THOMAS D, HARRIS PJ, et al: The role of endogenous angiotensin II in the regulation of renal hemodynamics and proximal fluid reabsorption in the rat. J Physiol 453:1-13, 1992
10. BOVEE KC, WONG PC, TIMMERMANS PB, et al: Effects of non-peptide angiotensin II receptors antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 4(4 Pt. 2):327S-333S, 1991
11. PRICE AD, DE'OLIVEIRA JM, FISHER ND, et al: Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 30:240-246, 1997
12. PARATI G, CASADEI R, GROPELLI AC, et al: Comparison of finger and intraarterial blood pressure monitoring at rest and during laboratory testing. Hypertension 13:647-655, 1989
13. COLE BR, GIANGIACOMO J, INGELFINGER JR, et al: Measurement of renal function without urine collection. N Engl J Med 287:1109-1114, 1972
14. HELLERSTEIN S, BERENBOM M, ALON U, et al: The renal clearance and infusion clearance of inulin are similar but not identical. Kidney Int 44:1058-1061, 1993
15. SCHMIEDER RE, GATZKA C, SCHOBEL H, et al: Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol 6:381-388, 1994
16. SMITH HW, FINKELSTERN N, ALIMINOSA L, et al: The renal clearance of substituted hippuric acid derivatives and other aromatic acids in dogs and man. J Clin Invest 24:388-398, 1945
17. MANN JF, JOHNSON AK, GANTEN D: Plasma angiotensin II: Dipsogenic levels and the angiotensin generating capacity of renin. Am J Physiol 238:R372-R377, 1980
18. NORUSIS MJ: SPSS for Windows. Advanced Statistics Release 6.0. Chicago, SPSS Inc., 1993
19. BROOKS DP, OHLSTEIN EH, RUFFOLO RR: Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data. Am Heart J 138:246-251, 1999
20. OHLSTEIN EH, BROOKS DP, FEUERSTEIN GZ: Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan, or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 55:244-251, 1997
21. OHLSTEIN EH, GELLAI M, BROOKS DP: The antihypertensive effect of the angiotensin II receptor antagonist DuP753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther 262:595-601, 1992
22. BURNIER M, RUTSCHMANN B, NUSSBERGER J, et al: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22:339-347, 1993
23. BURNIER M, HAGMAN M, NUSSBERGER J, et al: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25:602-609, 1995
24. WEIR MR, DZAU VJ: The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertens 12: 205-213, 1999
25. LASZLO Z, ROSSLER A, HINGHOFER-SZALKAY HG: Cardiovascular changes during and after different LBNP levels in men. Aviat Space Environ Med 69:32-39, 1998
26. LACOLLEY PJ, PANNIER BM, SLAMA MA: Carotid artery haemodynamics after mild degree of lower-body negative pressure in man. Clin Sci 83:535-540, 1992
27. TIDGREN B, HJEMDAHL P, THEODORSSON E, et al: Renal responses to lower body negative pressure in humans. Am J Physiol 259:573-579, 1990
28. HIRSCH AT, LEVENSON DJ, CUTLER SS, et al: Regional vascular responses to prolonged lower body negative pressure in normal subjects. Heart Circ Physiol 26:219-225, 1989
29. GREENLEAF JE, PETERSEN TW, GABRIELSEN A, et al: Low LBNP tolerance in men is associated with attenuated activation of the renin-angiotensin system. Am J Physiol 279:822-829, 2000
30. SUNDLOF G, WALLIN BG: Effect of lower body negative pressure on human muscle nerve sympathetic activity. J Physiol (Lond) 278: 525-532, 1978
31. WÜRZNER G, CHIOLERO A, MAILLARD M, et al: Renal and neurohumoral responses to increasing levels of lower body negative pressure in men. Kidney Int 60:1469-1476, 2001
32. JOHNSON JM, ROWELL LB, NIEDERBERGER M, et al: Human splanchnic and forearm vasoconstrictor responses to reductions of right atrial and aortic pressures. Circ Res 34:515-524, 1974
33. ZOLLER RP, MARK AL, ABBOUD FM, et al: The role of low pressure baroreceptors in reflex vasoconstrictor response in man. J Clin Invest 51:2967-2972, 1972
34. MISUMI J, GARDES J, GONZALES MF, et al: Angiotensinogen's role in ANG formation, renin release and renal hemodynamics in isolated perfused kidney. Am J Physiol 256:719-727, 1989
35. SCHMIEDER RE, SCHOBEL HP, GATZKA CE, et al: Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress. J Hypertens 14:1201-1207, 1996
36. BURNIER M, ROCH-RAMEL F, BRUNNER HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 49:1787-1790, 1996
37. BURNIER M, HAGMAN M, NUSSBERGER J, et al: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25:602-609, 1995
38. PECHÈRE-BERTSCHI A, NUSSBERGER J, DECOSTERD L, et al: Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 16: 385-393, 1998